Past performance
About Cohance Lifesciences Ltd Suven Pharmaceuticals Limited (SPL), established in 2018, is a bio-pharmaceutical company specializing in the development and manufacturing of New Chemical Entity (NCE) intermediates, Active Pharmaceutical Ingredients (APIs), specialty chemicals, and formulated drugs through contract research and manufacturing services (CRAMS). SPL’s core business model, Contract Development and Manufacturing Operations (CDMO), supports the global life sciences and fine chemicals sectors in NCE development. The company has a wholly owned subsidiary, Suven Pharma Inc., in the USA.
SPL has actively expanded its operations, including a Rs 320-crore capital expenditure plan initiated in 2019-20 and a USD 35 million investment in Rising Pharma Holdings, Inc., USA. The company also acquired Casper Pharma Private Limited in 2022. SPL has been successful in filing 17 Abbreviated New Drug Applications (ANDAs) by 2022, with nine approvals and launched eight products. These strategic expansions and investments underscore SPL's robust growth trajectory and commitment to enhancing its global pharmaceutical services footprint.
Performance overview